Press release: Nexus Medical Labs Achieves Improved Detection Limits Through Partnership with Lybe® Scientific
Lybe® Scientific will deliver its NAxtra® nucleic acid extraction kit to Nexus Medical Labs. The partnership further reinforces Nexus’ competitive advantages as a supplier of fast, compliant, and integration-ready diagnostic solutions.
“The NAxtra® Extraction kit captured our attention because of the overall simplicity of the workflow, the minimal reagent requirements, and the rapid time to result, all of which aids our high-throughput sample processing and workflows,” said Esther Brown, Vice President of Operations at Nexus Medical Labs.
The 60,000+ test unit agreement represents Nexus’s continued investment in cutting-edge extraction technologies to support its high-throughput sexually transmitted infection (STI) testing operations.
Improved Limit of Detection Exceeds Expectations
This partnership highlights Nexus Medical Labs’ continuous commitment to innovate and improve.
“Our R&D team conducted a literature search for new extraction technologies that could support our molecular workflows. A paper published about NAxtra magnetic nanoparticles sparked our initial interest,” said Esther Brown.
Following an initial phase of close collaboration and adaptation of the Lybe® Scientific products and protocols, Esther Brown says the NAxtra® nucleic acid extraction kit has exceeded their expectations: “We were expecting to simply match our current limit of detection (LOD) but were pleasantly surprised to see measurable improvement when using the NAxtra® extraction kit across our STI testing panels.”
Gaining Traction in Multiple Markets
Dr. Tonje Steigedal, CEO of Lybe® Scientific, is pleased to announce the deal.
“Nexus Medical Labs provides important support and services to health companies and other customers with specific and high demands for quality, technical capability, and speed. Being chosen as a supplier to such a forward-thinking and cutting-edge partner – who operates in a very demanding market – validates the value our products bring to modern diagnostic pipelines.”
The NAxtra® technology has also gained traction in the aquaculture industry, after years of delivering to the healthcare industry. Experiencing interest from the U.S. healthcare sector underscores the broad product catchment area of Lybe® Scientific’s products.
“Our NAxtra® technology suits all laboratories that value high precision and swift diagnostic workflows for biological samples. This deal confirms that our strategic investments in improving the limit of detection were correct and are in line with the actual needs in the market,” says Steigedal.
Close Partnership
Jill Sullivan, VP of Growth is happy with the partnership: “To date, our communication with Lybe®Scientific has been excellent, and we’ve been consistently impressed by the level of thought and technical insight they’ve offered to help us improve our results.”
Steigedal echoes the sentiment.
“Nexus Medical Labs is unwavering in their commitment to quality standards, documentation, speed, responsiveness and a constant improvement of their delivery. Cooperating with clients like Nexus Medical Labs – who are cutting-edge, customer-oriented and open in their communication – challenges us in the best possible way,” says Steigedal.
For more information or interviews, contact:
Jill Sullivan
VP of Growth
sales@nexusmedlabs.com
Tonje Steigedal, PhD
CEO
tonje@lybescientific.com
(+47) 905 52 334
About Nexus Medical Labs
Nexus Medical Labs is a U.S.-based, CLIA- and CAP-accredited laboratory specializing in high-quality, scalable diagnostic processing solutions for healthcare organizations, telehealth platforms, and clinical researchers. Uniquely positioned as both a high-performance clinical lab and a full-service contract research organization (CRO), Nexus helps partners move from concept to clinical deployment with speed and confidence. Through the CRO arm, Nexus provides early-stage diagnostic development, compatibility testing for novel sample types, comprehensive validation studies with complete documentation, and end-to-end R&D support to accelerate innovation. In parallel, the Nexus clinical laboratory operates as a seamless extension of its partners, providing high-throughput testing, validated workflows, and reliable turnaround times. Nexus also offers streamlined lab integrations and robust home-sample collection workflows that increase efficiency and expand access—while preserving an exceptional patient experience. Follow for more information, visit www.nexusmedlabs.com, and follow Nexus on LinkedIn.
About Lybe® Scientific
Lybe® Scientific is a Norwegian biotechnology company that delivers high-quality sample preparation products for swift and sensitive laboratory pipelines. Lybe’s first product, the NAxtra® nucleic acid extraction kit (CE IVD), was widely used for SARS-CoV-2 diagnostics in Norway and internationally, selling over 10 million reaction units. The company develops a proprietary platform technology for superior quality and nanoparticle-based nucleic acid extraction products. Products are tailored to a wide selection of sample types and applications. For more information, visit www.lybescientific.com and follow Lybe® on LinkedIn.
About NAxtra® nucleic acid extraction kit (CE IVD)
NAxtra® is a magnetic bead-based technology for RNA and DNA extraction from human naso- and oro-pharyngeal swab samples, saliva, urine or genital swab samples. Used for isolation and purification of bacterial or viral nucleic acids, preparing clinical samples for downstream qualitative diagnostics and analysis, such as PCR and next-generation sequencing. NAxtra® provides fast extraction, low limits of detection, and is easily adapted to manual and automated laboratory workflows.